Armin Ghobadi, MD, Discusses Trials Needed to Build on Blinatumomab Pilot Study Data

December 28, 2020
Armin Ghobadi, MD

Ghobadi detailed the next steps needed to build on the results of a study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

In an interview with CancerNetwork®, Armin Ghobadi, MD, of the Washington University School of Medicine in St. Louis, detailed the next steps needed to build on the results from a study (abstract #1450) of blinatumomab (Blincyto) presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

I think the result of [the abstract #1450 are] promising. That means we have to do more investigation. Still, 4 patients obviously relapsed later on, but we have ideas in terms of designing the next larger trial using T-cell engagers as consolidation after BEAM [carmustine, etoposide, cytarabine, and melphalan] autologous stem cell transplantation. I think this pilot trial shows that this is a promising strategy. We have to refine it and do it in a larger study—hopefully in a randomized fashion—to show that [by] using such a strategy, we can cure more patients. And hopefully more patients are going to be in a disease-free survival status later on after BEAM autologous transplant.